Circulating tumor DNA (ctDNA) is a revolutionary non-invasive tool for tracking tumor dynamics. A post-hoc analysis of the ALTER-C-002 study recently evaluated how ctDNA in metastatic CRC predicts clinical outcomes. Specifically, researchers investigated patients receiving first-line anlotinib combined with capecitabine and oxaliplatin (CAPEOX). These patients all had RAS and BRAF wild-type tumors, making them suitable candidates for this intensive regimen.

The study used a 90-gene next-generation sequencing (NGS) panel to quantify tumor burden in blood samples. Researchers measured the maximum somatic allele frequency (MSAF) at multiple time points to track therapeutic response. By analyzing plasma samples at baseline, near the best response, and at disease progression, the team established a clear link between genetic markers and clinical success. Consequently, this method offers a real-time window into treatment efficacy.

Monitoring ctDNA in metastatic CRC for Treatment Optimization

Results showed that baseline MSAF levels correlate strongly with patient survival. Furthermore, the dynamic changes in ctDNA in metastatic CRC during the first cycle of treatment served as an early warning sign for progression. Patients with a rapid decline in MSAF levels experienced significantly better progression-free survival (PFS) compared to those with stable or rising levels. Therefore, clinicians can potentially use these metrics to adjust therapy long before radiological changes appear on a CT scan.

Additionally, the study highlighted that MSAF is a more sensitive indicator of tumor burden than traditional protein biomarkers. However, liquid biopsies provide a more nuanced view of clonal evolution when compared to imaging alone. Monitoring these genetic shifts allows for a more personalized approach to oncology care. Moreover, the integration of these biomarkers into routine practice could optimize first-line treatment strategies for Indian patients.

What is MSAF in ctDNA analysis?

MSAF stands for Maximum Somatic Allele Frequency. It is a quantitative measure used to estimate the proportion of tumor-derived DNA fragments in the blood, serving as a proxy for overall tumor burden and genetic complexity.

How does ctDNA monitoring help in CRC treatment?

Serial ctDNA monitoring allows doctors to see molecular changes in the tumor before they are visible on a CT scan. This early insight helps in identifying treatment resistance or confirming a positive molecular response to therapy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Liu Y et al. Circulating tumor DNA as a prognostic biomarker in metastatic colorectal cancer: Post-hoc analysis of treatment response and survival outcomes in the ALTER-C-002 study. Biomol Biomed. 2026 Feb 24. doi: 10.17305/bb.2026.13678. PMID: 41732966.

2. Holz A, et al. Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis. Cancer Treat Rev. 2025 Sep;138:102999.

3. Ding KF, et al. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as first-line therapy. Cancer Commun. 2023 May;43(5):e15581.